NCT00939120 - Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Benign Prostatic Hyperplasia (BPH)

Interventions

DRUG

Tolterodine ER 4mg

1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily

DRUG

Placebo

1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily

DRUG

Pre-randomization Dutasteride

All participants were on Dutasteride 0.5mg orally once daily prior to randomization.

Trial Locations (1)

47630

Deaconess Clinic Gateway Health Center, Newburgh